SEC Form 4 · accession 0001209191-18-023581

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

David P Schenkein

Officer — Chief Executive Officer · Director

Period of report

Apr 2, 2018

Accepted (ET)

Apr 4, 2018 · 4:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001439222

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock	Apr 2, 2018	M	13,000	$0.3025	A	13,000	D
Common stock^F3	Apr 2, 2018	S	1,557	$75.54	D	11,443	D
Common stock^F4	Apr 2, 2018	S	2,600	$76.40	D	8,843	D
Common stock^F5	Apr 2, 2018	S	3,340	$77.76	D	5,503	D
Common stock^F6	Apr 2, 2018	S	3,390	$78.59	D	2,113	D
Common stock^F7	Apr 2, 2018	S	2,113	$79.49	D	0	D
Common stock^F8	holding	—	—		—	271,772	I	See footnote
Common stock^F9	holding	—	—		—	79,082	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F10	$0.3025	Apr 2, 2018	M	13,000	D	—	Aug 12, 2019	Common stock	13,000	78,567	D

Explanation of responses

F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F10This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013.
F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.00 to $75.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.02 to $77.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.10 to $78.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.11 to $79.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F7The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.16 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F8Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F9Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.